undergoing autologous stem cell transplant (ASCT; NCT05561751). Clinical trial results for this study are expected in Q4 2025. Current Evaluating Potential Indication Expansions – In addition to AML and MM, Exicure is evaluating a range of...
serious adverse outcomes in pregnant women with APS and their babies. The study results were published online on April 10, 2025 in Annals of the Rheumatic Diseases. “The IMPACT study represents a bold and very successful partnership over many years...
clinics in Australia. Pykus intends to submit an Investigational Device Exemption (IDE) application to the FDA in Q4 2025 for a multicenter U.S. pivotal trial, pending financing and regulatory discussions. The Company plans to meet with FDA in Q3...
Element Biosciences, a life sciences company democratizing access to advanced biological tools, is excited to announce the 2025 AVITI for Agrigenomics Accelerator Grant. This initiative seeks to advance research in plant and animal sciences by...
favorable pharmacokinetics and early signs of efficacy - SciTech is preparing to launch the SCLC trial in Q2/3 2025. The company anticipates that this trial will further validate the drug's broad therapeutic potential. "We are thrilled about the...
oral allergy medications like Benadryl®, making it a versatile, worry-free choice for families. Recognized as the 2025 Product of the Year in the Immediate Relief category, PBZ OTC is poised to become a staple in medicine cabinets nationwide. PBZ...
g/vial of Mylan Laboratories Limited, NDA 209481. According to IQVIA™ sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market2...
therapies for neurodegenerative diseases, today announced new data from its OVERTURE feasibility trial at the AD/PD™ 2025. The results showed that Spectris™, the company’s non-invasive investigational neuromodulation device, maintains corpus...
equivalent to recombinant keratinocyte growth factor (KGF). This product will be on the market beginning April 2025. Development of Synthetic Peptide Growth Factors by PeptiGrowth: Conventional growth factors and cytokines used in the manufacturing...
Hanmi Pharmaceutical plans to export Gugutams to the Mexican market for a period of seven years, starting in February 2025. Gugutams, developed by Hanmi Pharmaceutical, is the world's first urological combination therapy combining two active...
Society for Regenerative Medicine, scheduled to be held at Pacifico Yokohama in Yokohama, Japan from March 20 to March 22, 2025. The companies will showcase their research findings through poster presentations, focusing on the ongoing development...
common stock will begin trading under the new Nasdaq symbol “NAGE” at stock market open today, Wednesday, March 19, 2025. The CUSIP number for the Company's common stock will remain the same. With a legacy spanning over 25 years, this strategic...
outcomes of patients with r/r AML receiving Actimab-A + CLAG-M to CLAG-M alone. The trial is expected to be initiated in 2025. Sandesh Seth, Actinium's Chairman and CEO, said, "There is significant momentum for Actimab-A with the publication of...
Vilcek Foundation Prizes for Creative Promise in Biomedical Science are being accepted now through June 9, 2025. These $50,000 prizes are given each year to three early- to mid-career immigrant scientists living in the United States who have made...
therapy, and completion of this study moves us closer to making that goal a reality." About metastatic prostate cancer: In 2025 it is estimated that there will be 50,055 new cases of metastatic prostate cancer in the United States (de novo...
3 trial in psoriatic arthritis." UCB's data for BIMZELX in moderate-to-severe PSO will be presented as six posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, U.S., March 7–11.1-6 These abstracts complement...
pharmaceutical company Insilico Medicine, combining strengths to embark on a new journey in global AI drug R&D. In January 2025, Henlius, a subsidiary of Fosun Pharma, entered into a strategic collaboration with DP Technology for AI-assisted drug...
announced the appointment of Vincent (Vin) Colicchio as Senior Vice President of Operations, effective February 3, 2025. In this role, Vin will lead Cosette’s manufacturing, global supply chain, and operational strategy, ensuring efficiency, and...
clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing, completed February 3, 2025. “As the pace of healthcare innovation accelerates, pharmaceutical companies need partners who can help them scale...
properties. We will continue exploring its therapeutic potential to benefit patients worldwide." On January 10, 2025, Harbour BioMed and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech") entered into a global licensing agreement...
